FPRX Five Prime Therapeutics, Inc.

48.17
-0.04  -0.08%
Previous Close 48.21
Open 48.00
Price To book 3.24
Market Cap 1.31B
Shares 27,138,000
Volume 192,986
Short Ratio 6.80
Av. Daily Volume 365,802

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2 dose expansion phase initiated May 2016. Enrollment to be completed 2H 2017. Data due 2017.
FPA008
Pigmented Villonodular Synovitis (PVNS)
Phase 1b NSCLC halted, mesothelioma to continue. Data due at ESMO 8-12 September 2017. Exact date TBC.
FP-1039
Mesothelioma cancer

Latest News

  1. FIVE PRIME THERAPEUTICS INC Files SEC form 8-K, Change in Directors or Principal Officers
  2. Five Prime Therapeutics to Announce Fourth Quarter and Full Year 2016 Financial Results and Host Conference Call on February 23
  3. Five Prime Therapeutics to Present at the LEERINK Partners 6th Annual Global Healthcare Conference
  4. Five Prime to Present Preclinical Research Data at 2017 AACR Annual Meeting
  5. Cabiralizumab From Five Prime Therapeutics Inc (FPRX) Obtains Orphan Designation
  6. European Commission Grants Orphan Drug Designation to Cabiralizumab (FPA008) for Pigmented Villonodular Synovitis (PVNS)
  7. FIVE PRIME THERAPEUTICS INC Files SEC form 8-K, Results of Operations and Financial Condition, Regulation FD Disclosu
  8. Blog Coverage Five Prime Announced Extension of Collaboration Agreement by Bristol-Myers Squibb
  9. Bristol-Myers Extends Deal with Five Prime Therapeutics
  10. Five Prime Therapeutics and Bristol-Myers Squibb Extend Research Term in Collaboration to Discover Novel Immuno-Oncology Therapies for Three Immune Checkpoint Pathways
  11. Five Prime Therapeutics and Bristol-Myers Squibb Extend Research Term in Collaboration to Discover Novel Immuno-Oncology Therapies for Three Immune Checkpoint Pathways
  12. Five Prime Therapeutics to Present at the 35th Annual J.P. Morgan Healthcare Conference
  13. Five Prime Therapeutics, Inc. breached its 50 day moving average in a Bearish Manner : FPRX-US : December 13, 2016
  14. FIVE PRIME THERAPEUTICS INC Files SEC form 8-K, Entry into a Material Definitive Agreement
  15. Is TASER International, Inc. (TASR) Firing Blanks?
  16. ETFs with exposure to Five Prime Therapeutics, Inc. : December 8, 2016
  17. FIVE PRIME THERAPEUTICS INC Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits
  18. Is Five Prime Therapeutics Inc (FPRX) A Good Stock To Buy?
  19. Five Prime Presents Data from FPA144 in Urothelial Cancer at 28th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapies
  20. Five Prime Therapeutics to Host Research & Development Day on December 8, 2016